Face Masks Reduce the Release of Pseudomonas aeruginosa Cough Aerosols when Worn for Clinically-Relevant Time Periods by 
Face Masks Reduce the Release of Pseudomonas aeruginosa Cough
Aerosols when Worn for Clinically-Relevant Time Periods
CF Cough Aerosol Group (2018). Face Masks Reduce the Release of Pseudomonas aeruginosa Cough
Aerosols when Worn for Clinically-Relevant Time Periods. American Journal of Respiratory and Critical Care
Medicine. DOI: 10.1164/rccm.201805-0823LE
Published in:
American Journal of Respiratory and Critical Care Medicine
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2018 by the American Thoracic Society.  This work is made available online in accordance with the publisher’s policies. Please refer to
any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Aug. 2018
1 
 
Face masks reduce the release of Pseudomonas aeruginosa cough aerosols when worn for 1 
clinically-relevant time periods 2 
 3 
Rebecca E Stockwell1,2, Michelle E Wood1,2,3, Congrong He4, Laura J Sherrard5, Emma L 4 
Ballard6, Timothy J Kidd1,7, Graham R Johnson4, Luke D Knibbs8, Lidia Morawska4, Scott C 5 
Bell*1,2,3; CF Cough Aerosol Group. 6 
 7 
CF cough aerosol group members: 8 
Maureen Peasey, Christine Duplancic, Kay A Ramsay, Nassib Jabbour, Peter O’Rourke, 9 
Claire E Wainwright, Peter D Sly 10 
 11 
1Lung Bacteria Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, 12 
Herston QLD 4006, Australia 13 
2Faculty of Medicine, The University of Queensland, Herston QLD 4006, Australia 14 
3Adult Cystic Fibrosis Centre, The Prince Charles Hospital, 627 Rode Road, Chermside, QLD 15 
4032, Australia 16 
4International Laboratory for Air Quality and Health, Queensland University of Technology, 17 
Brisbane QLD 4000, Australia 18 
5Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7BL, United Kingdom 19 
6Statistical Support Group, QIMR Berghofer Medical Research Institute, 300 Herston Road, 20 
Herston QLD 4006, Australia 21 
7School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia 22 
QLD 4067, Australia 23 
8School of Public Health, The University of Queensland, Herston QLD 4006, Australia 24 
 25 
2 
 
Email: 26 
rebecca.stockwell@qimrberghofer.edu.au 27 
michelle.wood2@health.qld.gov.au 28 
c.he@qut.edu.au 29 
l.sherrard@qub.ac.uk 30 
emma.ballard@qimrberghofer.edu.au 31 
t.m.kidd@uq.edu.au 32 
g.johnson@qut.edu.au 33 
l.knibbs@uq.edu.au 34 
l.morawska@qut.edu.au 35 
scott.bell@qimrberghofer.edu.au 36 
 37 
*Corresponding author. Lung Bacteria Group, QIMR Berghofer Medical Research Institute, 38 
300 Herston Road, Herston, Brisbane QLD 4006, Australia. 39 
Tel: +61 7 3139 4770; Email: scott.bell@qimrberghofer.edu.au 40 
 41 
Author contributions: G.R.J., L.D.K., T.J.K., R.E.S., L.J.S., L.M. and S.C.B. conceived and 42 
designed the experiment. S.C.B., T.J.K. and L.M. led the funding applications with other 43 
members of the CF cough aerosol group (C.E.W and P.D.S.). M.E.W. and S.C.B. recruited 44 
the study participants. R.E.S. and C.H. conducted the cough studies. G.R.J. acquired the 45 
aerosol data. R.E.S. performed microbiological analysis. E.L.B. led the data analysis. R.E.S. 46 
and S.C.B. provide overall responsibility for the data and wrote the manuscript, with input 47 
from all co-authors. M.P., C.D., K.A.R., N.J., P.O., C.E.W and P.D.S. provided support to the 48 
study including analysis and/or microbiology expertise and/or clinical supervision.  49 
 50 
3 
 
Funding support: The project was funded by Cystic Fibrosis Foundation Therapeutics USA 51 
(BELL14AO). T.J.K. acknowledges National Health and Medical Research Council (NHMRC) 52 
Early Career (GNT10884488) and ERS-EU RESPIRE2 Marie Sklodowska-Curie Postdoctoral 53 
Research (#4571-2013) Fellowship support. L.D.K. acknowledges an NHMRC Early Career 54 
Fellowship (APP1036620). R.E.S acknowledges The Prince Charles Hospital Foundation and 55 
Advance Queensland PhD Scholarships. 56 
 57 
List ONE descriptor number that best classifies the subject of your manuscript: 9.17 58 
Cystic Fibrosis: Translational & Clinical Studies 59 
Total word count for the body of the manuscript = 1328 60 
  61 
4 
 
Abstract 62 
Introduction: The cystic fibrosis (CF) infection control guidelines recommend that people with 63 
CF wear face-masks when in communal areas of hospitals. Recently, we reported short-term 64 
wear of face-masks (~10-minutes) reduced the release of Pseudomonas aeruginosa aerosols 65 
during coughing. However, there is limited evidence to determine if face-masks continue to be 66 
effective at reducing the release of infectious cough aerosols after longer wear times. Methods: 67 
We recruited 25 people with CF and chronic P. aeruginosa infection and 10 healthy volunteers. 68 
All participants underwent up to 5 cough tests in a validated cough rig: 1) uncovered cough; 2) 69 
coughing with surgical mask worn for 10-minutes; 3) coughing with surgical mask worn for 70 
20-minutes; 4) coughing with a surgical mask worn for 40-minutes; 5) coughing with an N95 71 
respirator worn for 20-minutes (optional). The wear time of the mask included a 5-minute cough 72 
period in the aerosol collection rig. Sputum samples and cough aerosols were collected from 73 
participants with CF as previously described. All participants rated their level of comfort post-74 
test. Results: Surgical masks and N95 respirators were effective at reducing the release of P. 75 
aeruginosa aerosols during coughing after 40-minutes total wear and 20-minutes total wear 76 
respectively. Both participants with CF and healthy volunteers rated the surgical masks as more 77 
comfortable compared to N95 respirators. Conclusions: Surgical masks were the preferred 78 
interface to wear as source control and were effective at reducing the release of P. aeruginosa 79 
aerosols during coughing after 40-minutes of total wear.   80 
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Introduction 81 
Aerosol dissemination of respiratory pathogens may contribute to person-to-person 82 
transmission in people with cystic fibrosis (CF) [1]. This evolving knowledge of transmission 83 
modes has led to an update of the CF Foundation Infection and Prevention Control Guidelines 84 
recommending people with CF wear surgical masks in communal hospital areas to prevent the 85 
spread of CF respiratory pathogens [2]. These guidelines recommended the use of surgical 86 
masks as source control despite limited evidence for this application. 87 
 88 
We recently demonstrated that short-term wear of face-masks (10-minutes total wear) 89 
significantly reduces the release of Pseudomonas aeruginosa aerosols during coughing in 90 
people with CF [3]. These findings are consistent with an earlier study of people with CF that 91 
reached the same conclusion after very short-term wear of surgical masks (worn for 21 coughs) 92 
[4]. These results and a recent editorial to our short-term mask wear study [5] support our 93 
current aim to investigate the effectiveness, tolerability and functionality of face-masks as 94 
source control after extended wear. 95 
 96 
Methods 97 
We recruited 25 people with CF and chronic P. aeruginosa infection [6] from the Adult Cystic 98 
Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia. Ten healthy volunteers were 99 
recruited from hospital and research staff to assess mask comfort and mask weight change. All 100 
participants performed up to five randomly ordered tests in a validated cough system [7]: 1) 101 
uncovered cough; 2) coughing with surgical mask worn for 10-minutes); 3) coughing with 102 
surgical mask worn for 20-minutes; 4) coughing with surgical mask worn for 40-minutes; 5) 103 
coughing with N95 mask worn for 20-minutes [3, 7]. The N95 test was an optional test based 104 
on the poor comfort ratings observed in our earlier mask study [3]. 105 
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 106 
The duration of the mask wear tests were selected based on observation of patients moving 107 
around communal areas of the hospital described here. Two types of masks were tested: 108 
“surgical mask” [Catalogue # 47107; Halyard FLUIDSHIELD Level 3 Fog-Free Procedure 109 
Mask (∆P<2.5), Georgia, USA] and “N95 mask” [Catalogue # 46827 (small) or 46727 110 
(regular), Halyard FLUIDSHIELD N95 Particulate Filter Respirator and Surgical Mask, 111 
Georgia, USA]. New masks were used for each test. The total wear time of the masks included 112 
1-minute positioning of the participant into the rig, 2-minutes of tidal breathing with HEPA-113 
filtered air, a 5-minute cough period, followed by another 2-minutes of tidal breathing. Cough 114 
aerosol collection, sputum processing and P. aeruginosa genotyping were performed as 115 
previously described [1, 3, 8]. All participants rated their comfort levels after each test [3, 9]. 116 
All masks were weighed before and following each test. 117 
 118 
SPSS version 25 was used for statistical analysis. Participants with CF were stratified by the 119 
amount of aerosol colony forming units (CFU) produced during the uncovered cough test: high 120 
producer (total CFU was ≥10) or no/low producer (total CFU was <10) [3]. Categorical 121 
variables were examined using Pearson Chi-squared test or Fisher’s Exact test. Continuous 122 
variables were examined using a Student t-test or Mann-Whitney U test. CFU were log 123 
transformed and the paired t-test examined changes over time. The McNemar-Bowker test was 124 
used to examine comfort scores over time. The Wilcoxon Signed Rank Test was used to 125 
examine the change in mask weight over time. 126 
 127 
Results 128 
P. aeruginosa was cultured from the sputum of 25/25 participants with CF and was cultured in 129 
cough aerosols during the uncovered cough test of 20/25 participants (Table 1). P. aeruginosa 130 
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was cultured from cough aerosols of 9/20 participants during any of the surgical mask tests (10-131 
minutes, 20-minutes and 40-minutes total wear time) and 4/20 participants during the N95 mask 132 
test of 20-minutes total wear. The CFU were significantly reduced for the surgical mask tests 133 
compared with the uncovered cough test (p<0.001). Between mask tests, the CFU count 134 
remained similar as the duration of surgical mask wear increased as well as between mask types 135 
(Table 1). The P. aeruginosa strain types found in the cough aerosols were genetically 136 
indistinguishable from the paired sputum sample of each participant. 137 
 138 
Participants with CF rated surgical masks less comfortable than healthy volunteers for all test 139 
durations (surgical mask: 10-minutes, p=0.001; 20-minutes, p=0.007; 40-minutes, p=0.023; 140 
N95: 20-minutes, p=0.018) (Table 2). Participants with CF were more tolerant of surgical mask 141 
wear (good comfort) after 10- and 20-minutes total wear time if they had higher lung function, 142 
yet this difference was lost after 40-minutes of surgical mask wear. N95 masks were rated less 143 
comfortable in both participants with CF and healthy volunteers (Table 2). 144 
 145 
The change in mask weight for each test ranged from no weight change to a maximum weight 146 
change of 0.02g and was comparable between participants with CF and healthy volunteers 147 
(Table 2). There was a minor increase in surgical mask weight (median change, 0.01g) after 40-148 
minutes compared with 10-minutes wear (p=0.031) (Table 2). No statistical differences in mask 149 
weight change were seen in other time or mask type comparisons (Table 2). 150 
 151 
Discussion 152 
Our study demonstrates that face masks worn for clinically-relevant time periods are effective 153 
at reducing the release of potentially infectious aerosols during coughing in people with CF. 154 
These results extend upon our earlier observations that demonstrated surgical masks and N95 155 
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masks were both effective at reducing the release of infectious cough aerosols when the mask 156 
wear was of shorter duration [3]. The outcomes of our studies demonstrate that surgical masks 157 
are effective and tolerable as source control [3] and support the CF Foundation (USA) 158 
recommendations for surgical mask wear to reduce the risk of CF pathogen transmission in the 159 
hospital setting [2]. 160 
 161 
Surgical masks were the preferred mask type for source control in terms of comfort, which is 162 
similar to our short-term wear mask study findings [3]. Healthy volunteers tolerated the surgical 163 
masks better than those with CF and participants with CF who had higher lung function 164 
tolerated surgical masks better. When the comfort of surgical masks was assessed after extended 165 
wear in this cohort, a major finding was that the comfort ratings remained unchanged regardless 166 
of wear time for both people with and without CF. Therefore, surgical masks are not only 167 
effective but are also well tolerated by participants after 40-minutes total wear. 168 
 169 
An accompanying editorial of our recent mask study [3] questioned if mask dampness may 170 
affect the ability of the mask to function as source control after prolonged wear times [5]. The 171 
CF infection control guidelines indicate that masks being used as source control should be 172 
replaced when damp [2] and excessive moisture accumulation was a common reason for 173 
surgical mask replacement in people with tuberculosis using surgical masks as source control 174 
[10]. Our data indicates that although there was evidence of surgical mask moisture 175 
accumulation after 40-minutes total wear (estimated by increased weight), the surgical mask 176 
continued to function effectively as source control mitigating this concern. 177 
 178 
There are several limitations to this study: 1) The infectious dose of P. aeruginosa is unknown 179 
and therefore the infection risk cannot be determined; 2) Participants remained in view of staff 180 
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while wearing the masks and this may have modified the extent to which participants interfered 181 
with the mask leading to an incorrect estimation on the masks protective effects; 3) Participants 182 
were seated during the cough testing and this may have impacted on the participant’s ability to 183 
cough freely; 4) While some participants experienced episodes of spontaneous cough during 184 
testing, we were unable to differentiate between spontaneous and voluntary cough. Therefore, 185 
the protective effects of the masks may be overestimated; 5) The effectiveness and tolerability 186 
of masks is reported in adults only and these characteristics need to be studied in children; 6) 187 
Our study had a maximum wear time of 40-minutes and the effectiveness of masks worn for 188 
longer periods is unknown; 7) We did not assess inward protection provided by masks but this 189 
has been highlighted as an understudied field of research [11]. 190 
 191 
Our study confirms the effectiveness of surgical masks at reducing the release of P. aeruginosa 192 
cough aerosols in people with CF and provides evidence of patient tolerability and functionality 193 
of these masks as source control after 40-minutes of total wear. 194 
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Table 1: Demographic and clinical characteristics of the study participants 202 
  Group Production level in CF participants 
 Healthy CF p-value No/low (<10 CFU) 
High 
(≥ 10 CFU) p-value 
  (n = 10) (n = 25)  (n = 14) (n = 11)  
Participant characteristics       
Age, years, mean (SD) 37.3 (12.3) 33.3 (9.0) 0.29 36.7 (9.3) 28.9 (6.9) 0.029 
Sex, male, n (%) 6 (60.0) 15 (60.0) 1.00 9 (64.3) 6 (54.5) 0.70 
Body mass index (BMI), kg/m2, mean (SD) 24.6 (3.5) 22.8 (3.2) 0.14 22.5 (3.7) 23.1 (2.6) 0.63 
FEV1 % predicted, mean (SD) 92.6 (9.2) 53.8 (20.8) <0.001 54.2 (23.2) 53.3 (18.2) 0.91 
Mean P. aeruginosa sputum concentration, x 107 CFU/mL (95% CI)a n/a 5.2 (2.1 – 12.9) - 1.9 (0.7 – 5.7) 18.3 (4.7 – 70.9) 0.008 
Participants with P. aeruginosa detected in cough aerosols       
Uncovered cough test       
n (%) n/a 20 (80.0) - 9 (64.3) 11 (100.0)  
Mean CFU (95% CI)a  17 (7 - 43)  2 (1 – 4) 75 (34 – 165) <0.001d 
Surgical mask tests       
10-minutes total wear        
n (%) n/a 9 (36.0) - 1 (7.1) 8 (72.7)  
Mean CFU (95% CI)a  4 (1 – 10)  1 5 (1 – 13)  
20-minutes total wear       
n (%) n/a 9 (36.0) - 1 (7.1) 8 (72.7)  
Mean CFU (95% CI)a  4 (1 – 10)  1 4 (1 – 11) 0.99e 
40-minutes total wear       
n (%) n/a 9 (36.0) - 1 (7.1) 8 (72.7)  
Mean CFU (95% CI)a  3 (1 – 7)  1 4 (1 – 9) 0.56f, 0.64g 
N95 mask test~ 
20-minutes total wear (n=23) 
 
  
 
 
 
 
 
 
 
 
n (%) n/a 4 (17.4) - 0 (0.0)b 4 (40.0)c  
Mean CFU (95% CI)a  2 (0 – 6)  n/a 2 (0 – 6) 0.19h 
11 
 
Definitions: FEV1, forced expiratory volume in 1 second; CFU, colony forming unit; CFU/mL, CFU per millilitre of sputum; SD, standard deviation; 203 
CI, confidence interval, n/a, not applicable ~ Optional test  204 
 205 
ageometric mean 206 
bparticipant number (n) = 13 207 
cparticipant number (n) = 10 208 
dUncovered cough (geometric mean CFU) compared to each surgical mask test (geometric mean CFU) 209 
eSurgical masks (geometric mean CFU): 10-minutes versus 20-minutes total wear 210 
fSurgical masks (geometric mean CFU): 10-minutes versus 40-minutes total wear 211 
gSurgical masks (geometric mean CFU): 20-minutes versus 40-minutes total wear 212 
hMean CFU surgical mask 20-minutes total wear versus mean CFU N95 mask 20-minutes total wear  213 
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Table 2: Summary of mask properties 214 
 Mask comfort Mask weight change 
Mask properties Healthy n (%) 
CF 
n (%) p-value 
All participants 
Median (IQR) 
p-value 
Uncovered cough comfort level   1.00 n/a n/a 
Poor 0 (0.0 %) 0 (0.0 %)    
Sufficient 1 (10.0 %) 2 (8.0 %)    
Good 9 (90.0 %) 23 (92.0 %)    
Coughing wearing a surgical mask – 10-minutes total wear   0.001 0.01g (0.00g – 0.02g) n/a 
Poor 1 (10.0 %) 0 (0.0 %)    
Sufficient 0 (0.0 %) 15 (60.0 %)    
Good 9 (90.0 %) 10 (40.0 %)    
Coughing wearing a surgical mask – 20-minutes total wear   0.007 0.01g (0.00g – 0.02g) 0.73a 
Poor 1 (10.0 %) 1 (4.0 %)    
Sufficient 0 (0.0 %) 13 (52.0 %)    
Good 9 (90.0 %) 11 (44.0 %)    
Coughing wearing a surgical mask – 40-minutes total wear   0.023 0.02g (0.01g – 0.03g) 0.25b, 0.031c 
Poor 1 (10.0 %) 2 (8.0 %)    
Sufficient 1 (10.0 %) 15 (60.0 %)    
Good 8 (80.0 %) 8 (32.0 %)    
Coughing wearing N95 mask -20-minutes total wear   0.018 0.02g (0.00g – 0.04g) 0.21d 
Poor 0 (0.0 %) 11 (47.8 %)    
Sufficient 7 (77.8 %) 8 (34.8 %)    
Good 2 (22.2 %) 4 (17.4 %)     
 215 
aSurgical mask weight change: 10-minutes versus 20-minutes total wear 216 
bSurgical mask weight change: 20-minutes versus 40-minutes total wear 217 
cSurgical mask weight change: 10-minutes versus 40-minutes total wear 218 
dMask weight change after 20-minutes wear: surgical mask versus N95 mask 219 
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